Metanoia Bio

Metanoia Bio develops regenerative therapies using a proprietary platform focused on functional cell regeneration. Their approach aims to prevent and reverse chronic and age-related diseases by replacing old or damaged cells with healthy ones. The company leverages pharmacological methods that stimulate the body's natural mechanisms for cellular renewal rather than targeting single molecular pathways. Indications include diabetes, diabetic retinopathy, pancreatic cancer, Alzheimer's disease, heart failure, among others. The company has filed at least three patents related to these technologies but does not appear to have reached clinical-stage development yet.